Treatment and prevention of hepatic disorders

• US 5,922,757 A
• Filed: 09/30/1996
• Issued: 07/13/1999
• Est. Priority Date: 09/30/1996
• Status: Expired due to Fees

• Current Assignee: California University of San Francisco
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Chojkier, Mario
• Primary Examiner(s): Rotman, Alan L.
• Assistant Examiner(s): AULAKH, CHARANJIT
• Application Number:
  US08/723,052
• Time in Patent Office: 1,016 Days
• Field of Search: 514/458, 514/894, 549/408
• US Class Current: 514/458
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Abstract

New methods are described for the treatment of viral hepatitis C involving the administration of vitamin E and other compounds with antioxidant properties. Treatment with high doses of vitamin E is effective in treating chronic hepatitis C in patients refractory to interferon. In addition, new methods are described for the treatment of hepatic fibrosis and hepatic conditions manifesting hepatic fibrosis involving the administration of butylated hydroxytoluene and a metabolite of pentoxifylline, 1- 3-carboxypropyl!-3, 7-dimethylxanthine.

Claims

1. A method of treating hepatitis C, comprising:

a) providing i) a subject having symptoms of hepatitis C, and ii) a composition comprising d-α

-tocopherol; and

b) administering a therapeutic amount of said composition to said subject under conditions such that said symptoms are diminished.

2. The method of claim 1, wherein said subject is refractory to interferon.

3. The method of claim 1, wherein said antioxidant is administered orally to said subject.

4. The method of claim 1, wherein said antioxidant is administered parenterally to said subject.

5. The method of claim 1, further comprising the step prior to step b) of measuring said symptoms by liver biopsy.

6. The method of claim 5, further comprising the step subsequent to step b) of measuring said symptoms by liver biopsy.

15. The method of claim 1, wherein said therapeutic amount of said d-α

-tocopherol is from 800 units daily to 1600 units daily.

16. The method of claim 1, wherein said therapeutic amount of said d-α

-tocopherol is from 1000 units daily to 1400 units daily.

7. A method of treating hepatitis C, comprising:

a) providing i) a subject with hepatitis C having symptoms indicating fibrosis, and ii) d-α

-tocopherol; and

b) administering a therapeutic amount of said d-α

-tocopherol to said subject under conditions such that said symptoms are diminished.

8. The method of claim 7, wherein said subject is refractory to interferon.

9. The method of claim 7, wherein said d-α

-tocopherol is administered orally to said subject.

10. The method of claim 9, wherein said therapeutic amount of said d-α

-tocopherol is from 800 units daily to 1600 units daily.

11. The method of claim 10, wherein said therapeutic amount of said d-α

-tocopherol is from 1000 units daily to 1400 units daily.

12. The method of claim 7, wherein said d-α

-tocopherol is administered parenterally to said subject.

13. The method of claim 7, further comprising the step prior to step b) of measuring said symptoms by liver biopsy.

14. The method of claim 13, further comprising the step subsequent to step b) of measuring said symptoms by liver biopsy.